Trovagene Announces Issuance of Broad MicroRNA Patent

            Trovagene Announces Issuance of Broad MicroRNA Patent

Patent covers methods of detecting cell-free microRNA in urine and blood

PR Newswire

SAN DIEGO, July 24, 2013

SAN DIEGO, July 24, 2013 /PRNewswire/ --Trovagene, Inc. (NASDAQ: TROV), a
developer of cell-free molecular diagnostics, announced the issuance of US
patent 8,486,626, "Methods of detecting cell-free miRNA in urine and blood."
The patent pertains to the detection and quantitation of microRNA (miRNA)
using a wide variety of technologies and platforms. MicroRNAs are known to
play critical roles in cell development as well as a number of diseases,
including cancer.

(Logo: http://photos.prnewswire.com/prnh/20120620/LA28014LOGO)

"MicroRNA signatures are highly sensitive biomarkers with the potential to be
used in a wide range of molecular diagnostic tests," states Mark Erlander,
Ph.D., chief scientific officer of Trovagene. "They have been shown to have
varying expression levels across numerous pathological conditions including
cancer, autoimmune and inflammatory diseases and cardiovascular diseases."

Despite their relatively recent discovery and characterization, several
miRNA-based therapeutics have entered clinical trials, confirming their
importance as critical regulators of human disease. "MicroRNAs hold the
promise of yielding a new class of therapeutics in addition to current
diagnostic uses," adds Erlander.

The new miRNA patent extends Trovagene's established intellectual property
portfolio in the field of cell-free molecular diagnostics, which covers DNA
and RNA fragments found in urine. Trovagene already has proprietary methods
around the isolation, detection and analysis of these cell-free nucleic acids
from urine, a non-invasive and easy to obtain sample type.

"Cell-free nucleic acids, including microRNAs, are an integral part of our
company's focus on cancer diagnostics. Our newly established patent position
in microRNA detection in blood and urine will complement our proprietary
capabilities to detect and quantify DNA mutations and genetic variations,"
said Antonius Schuh, Ph.D., chief executive officer of Trovagene. "We believe
this technology promises to have a profound impact on the field of cancer
diagnostics."

About Trovagene, Inc.
Headquartered in San Diego, California, Trovagene is leveraging its patented
technology for the detection of cell-free DNA and RNA, short nucleic acid
fragments, originating from normal and diseased cell death that can be
isolated and detected from urine. Trovagene has a strong intellectual property
asset as it relates to cell-free DNA and RNA testing in urine. It has U.S. and
European patent applications and issued patents that cover testing for HPV and
other infectious diseases, cancer, transplantation, prenatal and genetic
testing.

Certain statements in this press release are forward-looking within the
meaning of the Private Securities Litigation Reform Act of 1995. These
statements may be identified by the use of forward-looking words such as
"anticipate," "believe," "forecast," "estimated" and "intend," among others.
These forward-looking statements are based on Trovagene's current expectations
and actual results could differ materially. There are a number of factors that
could cause actual events to differ materially from those indicated by such
forward-looking statements. These factors include, but are not limited to,
substantial competition; our ability to continue as a going concern; our need
for additional financing; uncertainties of patent protection and litigation;
uncertainties of government or fourth party payer reimbursement; limited sales
and marketing efforts and dependence upon fourth parties; and risks related to
failure to obtain FDA clearances or approvals and noncompliance with FDA
regulations. As with any medical diagnostic tests under development, there are
significant risks in the development, regulatory approval and
commercialization of new products. There are no guarantees that future
clinical trials discussed in this press release will be completed or
successful or that any product will receive regulatory approval for any
indication or prove to be commercially successful. Trovagene does not
undertake an obligation to update or revise any forward-looking statement.
Investors should read the risk factors set forth in Trovagene's Form 10-K for
the year ended December 31, 2012 and other periodic reports filed with the
Securities and Exchange Commission.

Contact:

Trovagene, Inc.

Stephen Zaniboni
Chief Financial Officer
Trovagene, Inc.
858-952-7594
szaniboni@trovagene.com

SOURCE Trovagene, Inc.

Website: http://www.trovagene.com
 
Press spacebar to pause and continue. Press esc to stop.